AMAG Pharmaceuticals (AMAG) Releases Earnings Results, Beats Expectations By $0.25 EPS

AMAG Pharmaceuticals (AMAG) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $1.45 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.25. Analysts had a consensus of $1.20. The company posted revenue of $132.50 million in the period, compared to analysts expectations of $122.96 million. The company’s revenue was up 46.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

AMAG Pharmaceuticals closed down -1.37 points or -4.95% at $26.33 with 10,08,562 shares getting traded on Monday. Post opening the session at $27.7, the shares hit an intraday low of $26.22 and an intraday high of $27.84 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Nov 10, 2015, John A. Fallon (director) purchased 3,230 shares at $31.20 per share price. According to the SEC, on Oct 2, 2015, William K Heiden (CEO) sold 2,000 shares at $39.69 per share price. On Aug 7, 2015, Frank E Thomas (President & COO) sold 15,000 shares at $66.85 per share price, according to the Form-4 filing with the securities and exchange commission.

AMAG Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on maternal health anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection) Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers such as those caused by oral surgery or ill-fitting dentures or braces.

AMAG Pharmaceuticals

Leave a Reply

AMAG Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on AMAG Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.